A Retrospective Study of the Efficacy and Safety of Hema-Plus (Recombinant Human Erythropoietin Alfa) in Patients with Chronic Kidney Disease who continuously used Hema-Plus at Siriraj Hospital

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

TCTR

Registry ID

TCTR20170808001

Enrollment

200

Registered

2017-08-08

Start date

2017-08-15

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

&#45

Interventions

Patients who received Hema&#45

Plus (erythropoietin alfa) for at least 6 months during 1 September 2013 to 31 December 2016.

Treatment

Erythropoietin alfa

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Each patient included in the review must meet all of the following criteria to be in this study: 1. Presented with chronic kidney disease 2. History of receiving Hema-Plus for at least 6 months during the study period

Exclusion criteria

Exclusion criteria: 1. Subjects who met inclusion criteria but their medical records are not available for access.

Design outcomes

Primary

Measure	Time frame
Mean hemoglobin values After treating with study drug Hemoglobin value,Adverse events After treating with study drug Adverse events,Proportion of patient achieving target hemoglobin value of 11-12 g/dL After treating with study drug Number of patient who achieved target hemoglobin,Mean difference between base line hemoglobin and follow up hemoglobin Before and after treating with study drug Hemoglobin value	—

Measure

Time frame

Mean hemoglobin values After treating with study drug Hemoglobin value,Adverse events After treating with study drug Adverse events,Proportion of patient achieving target hemoglobin value of 11-12 g/dL After treating with study drug Number of patient who achieved target hemoglobin,Mean difference between base line hemoglobin and follow up hemoglobin Before and after treating with study drug Hemoglobin value

—

Secondary

Measure	Time frame
NA NA NA	—

Countries

Thailand

Contacts

Public ContactDuanghathai Tinsulanonda

Siam Bioscience Co., Ltd.

duanghathait@siambioscience.com02 613 9939

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026

A Retrospective Study of the Efficacy and Safety of Hema&#45;Plus (Recombinant Human Erythropoietin Alfa) in Patients with Chronic Kidney Disease who continuously used Hema&#45;Plus at Siriraj Hospital